287 related articles for article (PubMed ID: 33186656)
1. PRMT6 deficiency induces autophagy in hostile microenvironments of hepatocellular carcinoma tumors by regulating BAG5-associated HSC70 stability.
Che N; Ng KY; Wong TL; Tong M; Kau PW; Chan LH; Lee TK; Huen MS; Yun JP; Ma S
Cancer Lett; 2021 Mar; 501():247-262. PubMed ID: 33186656
[TBL] [Abstract][Full Text] [Related]
2. CRAF Methylation by PRMT6 Regulates Aerobic Glycolysis-Driven Hepatocarcinogenesis via ERK-Dependent PKM2 Nuclear Relocalization and Activation.
Wong TL; Ng KY; Tan KV; Chan LH; Zhou L; Che N; Hoo RLC; Lee TK; Richard S; Lo CM; Man K; Khong PL; Ma S
Hepatology; 2020 Apr; 71(4):1279-1296. PubMed ID: 31469916
[TBL] [Abstract][Full Text] [Related]
3. PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation.
Chan LH; Zhou L; Ng KY; Wong TL; Lee TK; Sharma R; Loong JH; Ching YP; Yuan YF; Xie D; Lo CM; Man K; Artegiani B; Clevers H; Yan HH; Leung SY; Richard S; Guan XY; Huen MSY; Ma S
Cell Rep; 2018 Oct; 25(3):690-701.e8. PubMed ID: 30332648
[TBL] [Abstract][Full Text] [Related]
4. RNA m
Lin Z; Niu Y; Wan A; Chen D; Liang H; Chen X; Sun L; Zhan S; Chen L; Cheng C; Zhang X; Bu X; He W; Wan G
EMBO J; 2020 Jun; 39(12):e103181. PubMed ID: 32368828
[TBL] [Abstract][Full Text] [Related]
5. MYBL1 induces transcriptional activation of ANGPT2 to promote tumor angiogenesis and confer sorafenib resistance in human hepatocellular carcinoma.
Zhu J; Wu Y; Yu Y; Li Y; Shen J; Zhang R
Cell Death Dis; 2022 Aug; 13(8):727. PubMed ID: 35987690
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
[TBL] [Abstract][Full Text] [Related]
7. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
[TBL] [Abstract][Full Text] [Related]
8. Circ_0008305-mediated miR-660/BAG5 axis contributes to hepatocellular carcinoma tumorigenesis.
Yan F; Fan B; Wang J; Wei W; Tang Q; Lu L; Luo Z; Pu J; Yang SS
Cancer Med; 2021 Feb; 10(3):833-842. PubMed ID: 33481351
[TBL] [Abstract][Full Text] [Related]
9. PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression.
Luo T; Fu J; Xu A; Su B; Ren Y; Li N; Zhu J; Zhao X; Dai R; Cao J; Wang B; Qin W; Jiang J; Li J; Wu M; Feng G; Chen Y; Wang H
Autophagy; 2016 Aug; 12(8):1355-71. PubMed ID: 25905985
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia induces sorafenib resistance mediated by autophagy via activating FOXO3a in hepatocellular carcinoma.
Liang C; Dong Z; Cai X; Shen J; Xu Y; Zhang M; Li H; Yu W; Chen W
Cell Death Dis; 2020 Nov; 11(11):1017. PubMed ID: 33250518
[TBL] [Abstract][Full Text] [Related]
11. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
12. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
13. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
Zhou TY; Zhuang LH; Hu Y; Zhou YL; Lin WK; Wang DD; Wan ZQ; Chang LL; Chen Y; Ying MD; Chen ZB; Ye S; Lou JS; He QJ; Zhu H; Yang B
Sci Rep; 2016 Aug; 6():30483. PubMed ID: 27476430
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.
Zhai B; Hu F; Jiang X; Xu J; Zhao D; Liu B; Pan S; Dong X; Tan G; Wei Z; Qiao H; Jiang H; Sun X
Mol Cancer Ther; 2014 Jun; 13(6):1589-98. PubMed ID: 24705351
[TBL] [Abstract][Full Text] [Related]
16. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
Wang H; Xu H; Ma F; Zhan M; Yang X; Hua S; Li W; Li Y; Lu L
Cell Death Dis; 2020 Apr; 11(4):225. PubMed ID: 32269215
[TBL] [Abstract][Full Text] [Related]
17. The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma.
Augello G; Emma MR; Azzolina A; Puleio R; Condorelli L; Cusimano A; Giannitrapani L; McCubrey JA; Iovanna JL; Cervello M
Cancer Lett; 2021 Oct; 519():250-262. PubMed ID: 34314755
[TBL] [Abstract][Full Text] [Related]
18. SKP2 Promotes Hepatocellular Carcinoma Progression Through Nuclear AMPK-SKP2-CARM1 Signaling Transcriptionally Regulating Nutrient-Deprived Autophagy Induction.
Wei X; Li X; Yan W; Zhang X; Sun Y; Zhang F
Cell Physiol Biochem; 2018; 47(6):2484-2497. PubMed ID: 29991055
[TBL] [Abstract][Full Text] [Related]
19. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target.
Xue ST; Li K; Gao Y; Zhao LY; Gao Y; Yi H; Jiang JD; Li ZR
Autophagy; 2020 Oct; 16(10):1823-1837. PubMed ID: 31986961
[TBL] [Abstract][Full Text] [Related]
20. m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance.
Zhou T; Li S; Xiang D; Liu J; Sun W; Cui X; Ning B; Li X; Cheng Z; Jiang W; Zhang C; Liang X; Li L; Cheng X; Hui L; Wang H; Ding J
Signal Transduct Target Ther; 2020 Dec; 5(1):296. PubMed ID: 33361765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
